CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial
DOI 10.1055/s-0043-1771740
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB. Siegmund, S. Vermeire, B. E. Sands, M. C. Dubinsky, B. G. Feagan, R. Panaccione, V. Jairath, A. Yarur, M. Chiorean, J. Panés, M. Goetsch, C. J. Rabbat, P. Shah, J. Wu, S. Ghosh
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2023
Jahrgang / SeitenJg. 61 · S. e415-e416
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial
Zitieren
Zitierempfehlung
B. Siegmund, S. Vermeire, B. E. Sands, M. C. Dubinsky, B. G. Feagan, R. Panaccione, V. Jairath, A. Yarur, M. Chiorean, J. Panés, M. Goetsch, C. J. Rabbat, P. Shah, J. Wu, S. Ghosh (2023) Efficacy of etrasimod at Week 52 among patients with clinical response at Week 12 compared with the overall ulcerative colitis population: post hoc analysis of the phase 3 ELEVATE UC 52 trial. Zeitschrift für Gastroenterologie, 61 (08), e415-e416. https://doi.org/10.1055/s-0043-1771740
Mit CareLit weiterarbeiten